Vaccine against the nile fever virus
CA 2448796 C · Owner: Merial · Inventors: Loosmore, Sheena May; Audonnet, Jean-Christophe Francis
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns in vivo and in vitro expression vectors comprising a polynucleotide coding for the structural protein E of the Nile fever virus or the WN virus, optionally associated with a polynucleotide coding for the pre-membrane protein prM and/or for the membrane protein M, in particular in the form coding for prM-M-E. Said in vivo expression vectors are incorporated in live vaccines. The in vivo expression vectors are used for producing in vitro proteins which can then be used in subunit vaccines. The invention also concerns multivalent vaccines comprising a vaccine constituent against the WN virus and a vaccine constituent against another pathogen. The invention is …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 5, 2002 and granted November 20, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.